Portfolio augmentation for a potential biologic drug
Overview
Scientific informatics solutions play a critical role in expanding therapeutic pipelines by enabling data-driven decision-making across oncology research. In this case study, Excelra leveraged advanced scientific informatics solutions to help a biotech organization augment the portfolio of a biologic drug by identifying new solid tumor indications beyond its original hematological focus.
Excelra supported the program using its expertise in bioinformatics solutions and computational biology services, applying predictive analytics on large-scale cancer cohort datasets to drive AI-driven drug discovery. This approach aligns with Excelra’s broader capabilities in scientific informatics services and bioinformatics analytics, ensuring that insights were both biologically relevant and clinically actionable.
Our client
The client is a Europe-based biotechnology company operating in the oncology sector, focused on the development of large-molecule therapeutics. As part of its R&D strategy, the organization sought to strengthen its pipeline using scientific informatics solutions that could uncover new clinical opportunities while minimizing development risk.
Excelra partnered with the client as a scientific informatics consulting firm, combining oncology domain knowledge with scalable analytics frameworks. This collaboration was supported by Excelra’s experience in biopharma informatics solutions and its commitment to long-term scientific partnerships.
Client’s challenge
The client had a biologic drug candidate under development for blood cancer but lacked clarity on its potential efficacy across solid tumors. The primary challenge was identifying additional oncology indications supported by molecular evidence and biological rationale.
Addressing this challenge required integrating heterogeneous gene expression datasets, interpreting disease-specific molecular signatures, and correlating known drug response patterns—tasks that demand advanced cancer cohort analytics and robust scientific informatics solutions. Excelra’s approach drew upon proven methodologies discussed in its insights on big data and AI in drug discovery and analysis-ready clinical datasets.
Client’s goals
The client aimed to expand the therapeutic scope of its biologic drug by identifying solid tumor indications with a high likelihood of response. Key goals included reducing clinical uncertainty through data-driven drug discovery, prioritizing cancer sub-types using molecular evidence, and strengthening long-term portfolio value.
Achieving these objectives required scientific informatics solutions capable of managing complex biological data and enabling reproducible analytics. Excelra’s expertise in scientific data management ensured that the client’s data assets were structured, interoperable, and ready for advanced modeling.
Our approach
Excelra implemented an AI-enabled analytical framework built on iterative predictive modeling of patient-level and disease-level gene expression profiles. Using bioinformatics solutions and machine-learning classifiers, cancer indications were clustered and prioritized based on predicted drug responsiveness.
Excelra supported the program using its Computational Biology Services and expertise in scientific application development. The workflow leveraged predictive analytical models guided by insights from AI/ML predictive modeling, ensuring robustness and biological interpretability. This approach reflects Excelra’s strengths in AI-driven drug discovery and advanced data science services.
Conclusion
By applying scientific informatics solutions, Excelra enabled the successful augmentation of the client’s oncology portfolio by prioritizing ten cancer indications across solid and liquid tumors. Acute lymphoblastic leukemia (ALL) emerged as a top-priority indication, later validated independently by the client.
The engagement delivered subtype-level drug response predictions, identified causal gene signatures, and provided strong biological rationale—demonstrating how bioinformatics solutions and data-driven drug discovery accelerate confident decision-making in oncology R&D.
